Anti-inflammatory mechanism of alminoprofen: Action on the phospholipid metabolism pathway

Biochemical Pharmacology

Volumn 57, Issue 4, 1999, Pages 433-443

  Raguenes Nicol, Céline ^a   Russo Marie, Françoise ^a   Domage, Gisèle ^b   Diab, Nadia ^c   Solito, Egle ^a   Dray, Fernand ^c   Garcia MacE, José L ^b   Streichenberger, Gilles ^b  

^a INSERM   (France)

^b Ctr Rech Laboratoires Docteur E   (France)

^c Institut Cochin   (France)

Author keywords

Alminoprofen; Anti inflammatory drugs; Cyclooxygenase; Melittin; PLA2

Indexed keywords

6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; ALMINOPROFEN; DEXAMETHASONE; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; MEPACRINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENIDONE; PHOSPHOLIPASE A2; PIROXICAM; PROSTAGLANDIN SYNTHASE; TIAPROFENIC ACID;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; EDEMA; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RAT; SKIN FIBROBLAST;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EDEMA; FLURBIPROFEN; HUMANS; INDANS; INDOMETHACIN; ISOENZYMES; MELITTEN; MEMBRANE PROTEINS; PHOSPHOLIPASES A; PHOSPHOLIPIDS; PROPIONIC ACIDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS F; RATS; RATS, WISTAR;

EID: 0032922780     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00312-8     Document Type: Article

References (20)

1. Fujiyoshi T., Iida H., Hayashi I. Pharmacological profile and mode of action of alminoprofen, a non steroidal anti inflammatory drug. Jap Pharmacol Ther. 18:1990;159-180.
2. 2 a mediator between proximal and distal effectors of inflammation. Immunol Today. 12:(5):1991;143-146.
3. Vane J.R., Botting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 44:1995;1-10.
4. Fujiyoshi T., Iida H., Murakami M., Kuwashima M., Uematsu T. Pharmacological studies on EB 382, a new non steroidal anti inflammatory agent:mode of action of the analgesic effects. Chem Pharm Bull. 37:1989;775-777.
5. 2-induced oedema in rat paw. Eur J Pharmacol. 166:1989;505-510.
6. Shikada K., Tanaka S. Influence of epithelium on the inhibition of melittin-induced contraction of guinea-pig isolated trachea by the potassium channel opener NIP-121. Br J Pharmacol. 109:1993;1091-1096.
7. 3 cells. Endocrinology. 116:1983;1506-1513.
8. Vicart P., Testut P., Schwartz B., Liorens-Cortes C., Perdomo J.J., Paulin D. Cell adhesion markers are expressed by a stable human endothelial cell line transformed by the SV40 large T antigen under vimentin promoter control. J Cell Physiol. 157:1993;41-51.
9. 2 inhibitory proteins in human mononuclear cells. Eur J Biochem. 188:1990;139-146.
10. Dray F., Vuilliez-Le Normand B., Deroussent A., Briquet I., Gabellec M.M., Nakamura S., Wahl L.M., Gouyette A., Salahuddin S.Z. Active metabolism of arachidonic acid by Kaposi sarcoma cells cultured from lung biopsies; identification by HPLC and MS/MS of the predominant metabolite secreted as the 11.12-epoxy-eicosatrienoic acid. Biochim Biophys Acta. 1180:1992;83-90.
11. Karim S., Habib A., Levy-Toledano S., Maclouf J. Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 271:1996;12042-12048.
12. 2 and signal transduction. J Am Soc Nephrol. 3:1992;128-150.
13. 2 enzymes:Regulation and inhibition. Tips. 14:1993;92-98.
14. Hartman D.A., Tomchek L.A., Lugay J.R., Lewin A.C., Chau T.T., Carlson R.P. Comparison of the anti-inflammatory and anti-allergic drugs in the melittin- and D49 PLA2-induced mouse paw oedema models. Agents Actions. 34:1991;84-88.
15. 2 in the pathobiology of disease. Lab Invest. 55:1986;391-404.
16. 2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br J Dermatol. 112:1985;135-141.
17. 2 in rheumatoid synovial fluid. Life Sci. 36:1985;579-584.
18. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA and Serhan CN, Leukotrienes and lipoxins:structures, biosynthesis and biological effects. Science 237: 1171, 1987.
19. Zipser R.D., Giacomo L. Prostaglandins, thromboxanes and leukotrienes in clinical medicine. Western J Med. 143:1985;485-489.
20. 2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell. 80:1995;919-927.